Kolon TissueGene (XKRX:950160) Long-Term Capital Lease Obligation : ₩5,274 Mil (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Kolon TissueGene Long-Term Capital Lease Obligation?

Kolon TissueGene's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩5,274 Mil.

Kolon TissueGene's quarterly Long-Term Capital Lease Obligation declined from Jun. 2024 (₩5,494 Mil) to Sep. 2024 (₩4,978 Mil) but then increased from Sep. 2024 (₩4,978 Mil) to Dec. 2024 (₩5,274 Mil).

Kolon TissueGene's annual Long-Term Capital Lease Obligation declined from Dec. 2022 (₩6,273 Mil) to Dec. 2023 (₩5,568 Mil) and declined from Dec. 2023 (₩5,568 Mil) to Dec. 2024 (₩5,274 Mil).

Kolon TissueGene Long-Term Capital Lease Obligation Historical Data

The historical data trend for Kolon TissueGene's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kolon TissueGene Long-Term Capital Lease Obligation Chart

Kolon TissueGene Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

6,647.17

6,577.84

6,273.38

5,567.90

5,273.73

Kolon TissueGene Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															5,567.90	5,572.45	5,493.57	4,978.42	5,273.73

Kolon TissueGene (XKRX:950160) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Kolon TissueGene Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Kolon TissueGene's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Kolon TissueGene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kolon TissueGene Inc (XKRX:950160) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

9713 Key West Avenue, Suite 300, Rockville, MD, USA, 20850

Website

https://www.tissuegene.com

Kolon TissueGene Inc is a biopharmaceutical company that develops regenerative therapies for the treatment of various orthopedic disorders. It is developing four product candidates, TG-C, TG-B, TG-D and TG-N for regeneration of cartilage, bone, disc and nerve.

Kolon TissueGene Headlines

No Headlines